恩华药业发布上半年业绩，归母净利润7亿元，增长11.38%

Core Insights - Enhua Pharmaceutical (002262.SZ) reported a revenue of 3.01 billion yuan for the first half of 2025, representing a year-on-year growth of 8.93% [1] - The net profit attributable to shareholders was 700 million yuan, an increase of 11.38% year-on-year [1] - The basic earnings per share stood at 0.69 yuan [1] R&D Investment and Projects - The company has over 70 ongoing research projects with a research expenditure of 395 million yuan, reflecting a growth of 23.97% compared to the same period last year [2] - In the area of innovative drug development, there are currently 17 ongoing projects, including 1 project that has completed Phase III clinical trials and 2 projects that have completed Phase II trials [2] - The company is also engaged in 48 generic drug projects, with 1 project having received production approval and 5 projects currently under review for production [2]